iTeos Therapeutics, Inc.
ITOS
$7.77
$0.273.60%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -13.55% | -4.53% | -4.19% | -7.28% | 6.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.87% | 28.37% | 13.45% | 14.30% | 24.87% |
| Operating Income | 14.87% | -28.37% | -13.45% | 68.57% | -88.84% |
| Income Before Tax | 6.91% | -28.98% | -29.00% | 85.28% | -150.85% |
| Income Tax Expenses | -50.32% | 211.26% | 289.92% | 83.52% | 84.65% |
| Earnings from Continuing Operations | 9.43% | -43.08% | -40.68% | 79.22% | -145.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.43% | -43.08% | -40.68% | 79.22% | -145.75% |
| EBIT | 14.87% | -28.37% | -13.45% | 68.57% | -88.84% |
| EBITDA | 15.01% | -28.29% | -13.33% | 69.14% | -89.31% |
| EPS Basic | 24.92% | -18.58% | -16.70% | 81.27% | -144.88% |
| Normalized Basic EPS | 22.84% | -6.89% | -7.01% | 86.74% | -150.02% |
| EPS Diluted | 25.19% | -18.70% | -16.70% | 81.25% | -143.18% |
| Normalized Diluted EPS | 22.84% | -6.89% | -7.01% | 86.74% | -150.02% |
| Average Basic Shares Outstanding | 20.64% | 20.66% | 20.55% | 10.99% | 0.36% |
| Average Diluted Shares Outstanding | 20.64% | 20.66% | 20.55% | 10.99% | 0.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |